Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Negrier

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Blood|September 28, 2014
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialPeter W Collins, Guy Young, Karin Knobe, et al.
British Journal of Haematology|April 25, 2009
A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective studyYesim Dargaud, Lucia Rugeri, Marie Christine Vergnes, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
The New England Journal of Medicine|July 11, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 StudyJohannes Oldenburg, Johnny N Mahlangu, Willem Bujan, et al.
Blood|January 13, 2016
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trialElena Santagostino, Uri Martinowitz, Toshko Lissitchkov, et al.
The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.
Blood|March 7, 2024
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trialGili Kenet, Beatrice Nolan, Bulent Zulfikar, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
Nature Medicine|April 8, 2015
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophiliaAlfica Sehgal, Scott Barros, Lacramioara Ivanciu, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Blood|September 28, 2014
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialPeter W Collins, Guy Young, Karin Knobe, et al.
British Journal of Haematology|April 25, 2009
A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective studyYesim Dargaud, Lucia Rugeri, Marie Christine Vergnes, et al.
Blood|September 24, 2004
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia BAmy D Shapiro, Jorge Di Paola, Alice Cohen, et al.
The New England Journal of Medicine|July 11, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 StudyJohannes Oldenburg, Johnny N Mahlangu, Willem Bujan, et al.
Blood|January 13, 2016
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trialElena Santagostino, Uri Martinowitz, Toshko Lissitchkov, et al.
The New England Journal of Medicine|August 30, 2018
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsJohnny Mahlangu, Johannes Oldenburg, Ido Paz-Priel, et al.
Blood|March 7, 2024
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trialGili Kenet, Beatrice Nolan, Bulent Zulfikar, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
Nature Medicine|April 8, 2015
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophiliaAlfica Sehgal, Scott Barros, Lacramioara Ivanciu, et al.
Pageof 7